Collegium Pharmaceutical (COLL) Equity Average (2015 - 2026)

Collegium Pharmaceutical's Equity Average history runs 12 years deep, the most recent figure standing at $307.0 million for Q1 2026.

• In Q1 2026, Equity Average rose 32.56% year-over-year to $307.0 million; the TTM figure through Mar 2026 stood at $307.0 million (up 32.56% YoY), while the FY2025 annual figure was $265.3 million, up 25.04% from the prior year.
• Equity Average was $307.0 million for Q1 2026 at Collegium Pharmaceutical, up from $288.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $307.0 million in Q1 2026 to a low of $187.2 million in Q4 2023.
• Historically, Equity Average has averaged $220.2 million across 5 years, with a median of $208.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Equity Average fell 21.69% in 2022, then soared 32.56% in 2026.
• A 5-year view of Equity Average shows it stood at $196.0 million in 2022, then decreased by 4.52% to $187.2 million in 2023, then grew by 23.73% to $231.6 million in 2024, then gained by 24.48% to $288.2 million in 2025, then gained by 6.52% to $307.0 million in 2026.
• The last three Equity Average figures came in at $307.0 million (Q1 2026), $288.2 million (Q4 2025), and $253.5 million (Q3 2025), per Business Quant data.